- Home
- LGL vs BTAI Comparison
LGL vs BTAI Comparison
Compare LGL & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGL
- BTAI
- Stock Information
- Founded
- LGL 1917
- BTAI 2017
- Country
- LGL United States
- BTAI United States
- Employees
- LGL N/A
- BTAI N/A
- Industry
- LGL Industrial Machinery/Components
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- LGL Technology
- BTAI Health Care
- Exchange
- LGL Nasdaq
- BTAI Nasdaq
- Market Cap
- LGL 31.5M
- BTAI 28.7M
- IPO Year
- LGL N/A
- BTAI 2018
- Fundamental
- Price
- LGL $6.26
- BTAI $0.34
- Analyst Decision
- LGL
- BTAI Strong Buy
- Analyst Count
- LGL 0
- BTAI 4
- Target Price
- LGL N/A
- BTAI $5.00
- AVG Volume (30 Days)
- LGL 2.4K
- BTAI 1.0M
- Earning Date
- LGL 11-13-2024
- BTAI 11-14-2024
- Dividend Yield
- LGL N/A
- BTAI N/A
- EPS Growth
- LGL 66.76
- BTAI N/A
- EPS
- LGL 0.07
- BTAI N/A
- Revenue
- LGL $4,130,000.00
- BTAI $2,276,000.00
- Revenue This Year
- LGL N/A
- BTAI $164.86
- Revenue Next Year
- LGL N/A
- BTAI $69.74
- P/E Ratio
- LGL $90.88
- BTAI N/A
- Revenue Growth
- LGL 26.49
- BTAI 83.25
- 52 Week Low
- LGL $4.86
- BTAI $0.30
- 52 Week High
- LGL $6.76
- BTAI $4.17
- Technical
- Relative Strength Index (RSI)
- LGL 58.05
- BTAI 34.25
- Support Level
- LGL $5.88
- BTAI $0.35
- Resistance Level
- LGL $5.95
- BTAI $0.52
- Average True Range (ATR)
- LGL 0.11
- BTAI 0.06
- MACD
- LGL 0.01
- BTAI -0.00
- Stochastic Oscillator
- LGL 96.90
- BTAI 15.92
About LGL LGL Group Inc. (The)
LGL Group Inc is a holding company engaged in services, merchant investment and manufacturing business activities. The company has two reportable segments; Electronic Instruments and Merchant Investment. The Electronic Instruments segment, which generates key revenue, is focused on designing and manufacturing high-performance Frequency and Time reference standards that form the basis for timing and synchronization in various applications including satellite communication, time transfer systems, network synchronization, electricity distribution, and metrology. The Merchant Investment segment comprises various investment vehicles in which the company invests its capital.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.